주요우울장애(MDD) : 8개 시장의 의약품 예측과 시장 분석 - 업데이트판(2025년)

This report covers the 8 major markets and provides an Excel-based forecast model for the Major Depressive Disorder market through 2029.

GlobalData estimated that drug sales for MDD in 2019 were approximately $4.73 billion across the 8MM. The US market makes up the majority of total global sales, contributing $3.35 billion (70.7%) due to the large MDD prevalent population, combined with the high price of medication in the country. GlobalData anticipates that the MDD market will grow to be worth approximately $9.55 billion by 2029, at a compound annual growth rate (CAGR) of 7.3%. The US is expected to maintain its position as the market leader in 2029, increasing the proportion of global sales it accounts for to 84.7%

The major drivers of growth in the MDD market in the 8MM over the forecast period include:

The launch of six new pipeline products throughout the 8MM, which will have significantly higher costs of therapy when compared with the cost of the most commonly used MDD treatments that have high generic availability.

In the 8MM, the number of 12-month total prevalent cases of MDD is expected to increase during the forecast period.

Scope

• Overview of major depressive disorder (MDD), including epidemiology, symptoms, diagnosis, and disease management.
• Annualized MDD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2019 to 2029.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MDD treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 8MM MDD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM MDD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Major Depressive Disorder: Executive Summary

• 1.1 MDD therapeutics market will grow to $9.5 billion by 2029
• 1.2 Key players will struggle to maintain their competitive position
• 1.3 Better efficacy and rapid onset of action are the most pressing unmet needs in the MDD market
• 1.4 Novel late-stage pipeline drugs will be a key driver of growth
• 1.5 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
• 3.2 Disease staging systems
• 3.3 Prognosis
• 3.4 Quality of life

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 Forecast methodology
  • 4.4.1 Sources used
  • 4.4.2 Sources not used
  • 4.4.3 Forecast assumptions and methods
  • 4.4.4 Forecast assumptions and methods: 12-month total prevalence of MDD
  • 4.4.5 Forecast assumptions and methods: 12-month total prevalence of MDD by severity
• 4.5 Epidemiological forecast for MDD (2019-29)
  • 4.5.1 12-month total prevalent cases of MDD
  • 4.5.2 Age-specific 12-month total prevalence of MDD
  • 4.5.3 Sex-specific 12-month total prevalent cases of MDD
  • 4.5.4 12-month total prevalent cases of MDD by severity for ages <18 years
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Competitive Assessment

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Rapid onset of action
• 7.3 New therapies with better efficacy
• 7.4 Improved safety profiles
• 7.5 Management of patient outcome expectations

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Novel MOAs
  • 8.1.2 Development of adjunctive therapies
  • 8.1.3 Digital therapeutics
  • 8.1.4 Personalized treatments/biomarkers
• 8.2 Clinical trials design
  • 8.2.1 Study design
  • 8.2.2 Endpoints
  • 8.2.3 Placebo response rate

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment
  • 10.2.1 Monotherapies
  • 10.2.2 Adjunctive therapies

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers
• 12.5 Canada
  • 12.5.1 Forecast
  • 12.5.2 Key events
  • 12.5.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs interviewed for this report.
  • 13.4.1 KOLs
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Managing Epidemiologist
  • 13.6.5 Vice President of Disease Intelligence and Epidemiology
  • 13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence
• About GlobalData
• Contact Us